Published in Am J Hematol on May 01, 2006
The diagnostic dilemma of congenital unstable hemoglobinopathies. Pediatr Blood Cancer (2010) 0.82
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev (2006) 4.46
Retracted Genetic signatures of exceptional longevity in humans. Science (2010) 4.33
Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet (2005) 4.21
HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mutat (2002) 3.65
Genetic signatures of exceptional longevity in humans. PLoS One (2012) 3.20
Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature (2004) 2.98
Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis (2007) 2.60
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2003) 2.55
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol (2010) 2.55
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet (2011) 2.51
Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood (2009) 2.50
Fetal hemoglobin in sickle cell anemia. Blood (2011) 2.44
A network model to predict the risk of death in sickle cell disease. Blood (2007) 2.39
The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer (2010) 2.36
Imputation of missing genotypes: an empirical evaluation of IMPUTE. BMC Genet (2008) 2.34
Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood (2010) 2.25
Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res (2004) 2.24
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
HbVar database of human hemoglobin variants and thalassemia mutations: 2007 update. Hum Mutat (2007) 2.22
Fetal hemoglobin in sickle cell anemia: a glass half full? Blood (2013) 2.19
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood (2007) 2.13
Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr (2003) 2.11
A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. Am J Hematol (2013) 2.06
Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol (2009) 2.05
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood (2002) 2.02
Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr (2003) 2.00
Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly). Nat Genet (2002) 1.99
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest (2011) 1.89
Hemolysis-associated priapism in sickle cell disease. Blood (2005) 1.86
The paradox of hemoglobin SC disease. Blood Rev (2003) 1.75
Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.75
Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One (2008) 1.75
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) (2004) 1.67
Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood (2012) 1.66
Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign. Br J Haematol (2013) 1.63
Medical care utilization and mortality in sickle cell disease: a population-based study. Am J Hematol (2005) 1.61
Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.60
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood (2011) 1.54
Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype. Blood Cells Mol Dis (2013) 1.54
Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol (2003) 1.53
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood (2002) 1.52
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood (2013) 1.52
Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol (2006) 1.51
Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer (2005) 1.51
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.50
Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med (2006) 1.50
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol (2013) 1.49
A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. Blood (2011) 1.47
Bone marrow transplant options and preferences in a sickle cell anemia cohort on chronic transfusions. Pediatr Blood Cancer (2012) 1.46
Determining the cause of patchwork HBA1 and HBA2 genes: recurrent gene conversion or crossing over fixation events. Haematologica (2006) 1.45
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Med (2011) 1.45
Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am (2008) 1.43
Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood (2012) 1.43
Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr (2010) 1.43
Prenatal exclusion of beta thalassaemia major by examination of maternal plasma. Lancet (2002) 1.41
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood (2012) 1.37
Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol (2010) 1.34
Retraction. Science (2011) 1.32
BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis (2009) 1.32
Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol (2004) 1.30
Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer (2008) 1.30
Hemozoin-generated vapor nanobubbles for transdermal reagent- and needle-free detection of malaria. Proc Natl Acad Sci U S A (2013) 1.28
Pulmonary hypertension and NO in sickle cell. Blood (2010) 1.28
Unexpectedly low pulse oximetry measurements associated with variant hemoglobins: a systematic review. Am J Hematol (2010) 1.26
Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood (2011) 1.26
Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol (2005) 1.26
Fetal hemoglobin in sickle cell anemia: molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. Am J Hematol (2011) 1.26
Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. Am J Hematol (2008) 1.25
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res (2010) 1.24
Brain imaging findings in pediatric patients with sickle cell disease. Radiology (2003) 1.22
Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong Kong. Am J Hematol (2008) 1.22
Pseudoscore-based estimation from biased observations. Stat Med (2007) 1.20
Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol (2011) 1.19
Bayesian methods for multivariate modeling of pleiotropic SNP associations and genetic risk prediction. Front Genet (2012) 1.19
Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol (2011) 1.18
Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg (2003) 1.18
Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood (2007) 1.17